Stargardt Disease Therapeutics Market Overview

The global Stargardt Disease Therapeutics market is expected to exhibit a CAGR of 28.8% during the forecast period (2023-2030). Therapeutics for the management and possibly slowing of the progression of Stargardt disease, a genetic retinal illness that damages the macula and causes loss of central vision, are referred to as Stargardt disease. While there is presently no treatment for Stargardt disease, there are a number of therapeutic options being investigated.
 

Stargardt Disease Therapeutics Market Dynamics

Pharmacological drugs are being developed to target specific processes involved in the progression of Stargardt disease, such as inflammation, oxidative stress, and the buildup of harmful metabolites in the retina. For example, Belite Bio is conducting a Phase 3 clinical trial of the oral drug Tinlarebant, which is designed to inhibit retinol-binding protein 4 (RBP4) and slow the progression of the disease.
 
Gene therapy is another promising approach for treating Stargardt disease. Researchers at the National Eye Institute have developed a new stem-cell-based model that could be used to develop gene therapy treatments for the disease. This model has shown that Stargardt-related ABCA4 gene mutations damage a layer of cells in the eye known as the retinal pigment epithelium (RPE). This finding provides a new target for gene therapy treatments.
 
To know more insights – Download Sample
 
However, the lack of skilled professionals is a challenge for the Stargardt disease therapeutics market. There is a need for more skilled professionals to work in research and development, clinical trials, and manufacturing of Stargardt disease therapeutics.
 

Stargardt Disease Therapeutics Market Segment Analysis

By Drug Type 

  • LBS-008
  • Emixustat
 

By Age Group

  • Children
  • Adult

 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East and Africa

 

Major Companies Covered

Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG among others.

 

About us

DataM Intelligence 4 Market Research is a premier market research and business consulting firm that empowers businesses with accurate, reliable, and real-time market data and insights across a wide range of industries. Established in 2017, we have collaborated with over 750 companies, delivering valuable market intelligence for more than 6000 markets. Our expertise, extensive industry coverage, and robust research methodology have earned us the trust of our clients, making us their go-to partner for market intelligence needs.

 

At DataM Intelligence, we provide comprehensive, insightful, and actionable market intelligence, helping businesses navigate complex market landscapes and make informed decisions. Our dedicated team of analysts and industry experts possess in-depth knowledge and experience in their respective fields, ensuring the highest levels of accuracy and data integrity. Choose DataM Intelligence for all your market research and business consulting needs and experience the difference our commitment to excellence can make for your business.

 

Media Contact

Company Name: DataM Intelligence
Contact Person: Sravya Teja
Email: info@datamintelligence.com
Phone:+1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/

Comments (0)
No login
color_lens
gif
Login or register to post your comment
arrow_back